Sysmex : Presentation( PDF format / 411KB )

Business Results

First Nine Months of the

Fiscal Year Ending March 31, 2022

February 10, 2022

Sysmex Corporation

Index

Business Results, First Nine Months of the

Fiscal Year Ending March 31, 2022

The Sysmex Group adopted International Financial Reporting Standards (IFRS) in the fiscal year ended March 31, 2017.

Figures are disclosed in compliance with IFRS.

Forward-Looking Statements

This material contains forward-looking statements about Sysmex Corporation and its Group companies (the Sysmex Group). These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements or financial position either expressed or implied within these forward-looking statements.

Financial Highlights (Year on Year)

				258.9
(Billions of yen)
	208.3	218.1	211.8	49.8
202.5

44.5	42.5	40.4
		35.9

32.9

30.5	28.9
	26.4
	23.2

2018	2019	2020	2021	2022
(First nine months of years to March 31)

Net sales

Operating profit

Profit attributable to owners of the parent

	First nine months of	First nine months of
	fiscal year ending	fiscal year ended
	March 31, 2022	March 31, 2021
1USD	¥111.1	¥106.1
1EUR	¥130.6	¥122.4
1CNY	¥17.3	¥15.4

	First nine months of	First nine months of
	fiscal year ending	fiscal year ended	YoY (Previous
	March 31, 2022	March 31, 2021
(Billions of yen)	period = 100%)
	Results	Ratio	Results	Ratio
Net sales	258.9	100%	211.8	100%	122.2%
Cost of sales	121.5	46.9%	103.2	48.7%	117.7%
SG&A expenses	67.2	26.0%	58.2	27.5%	115.6%
R&D expenses	18.3	7.1%	15.2	7.2%	119.9%
Other income (expenses)	(1.9)	(0.7)%	0.7	0.4%	-
Operating profit	49.8	19.3%	35.9	16.9%	138.9%
Profit attributable to owners	32.9	12.7%	23.2	11.0%	141.3%
of the parent

• Net sales: Net sales rose significantly, owing to a recovery in testing demand (which lifted reagent sales) and the impact of exchange rates (yen depreciation).
• Operating profit: SG&A expenses increased. Even so, operating profit grew significantly thanks to higher sales,

which pushed up gross profit and improved the cost of sales ratio.

Exchange rate fluctuations raised net sales ¥15.30 billion and increased operating profit ¥5.26 billion. At the exchange rates prevailing one year earlier, net sales would have been up 15.0% year on year, and operating profit up 24.2%.

• Profit attributable to owners of the parent: Profit was up due to higher operating profit and an improvement in exchange gains (losses).

Exchange gains (losses): Gain of ¥0.44 billion (loss of ¥0.64 billion in same period of previous fiscal year)

3

Quarterly Operating Performance

The Company recorded double-digit growth in net sales compared with Q3 of the previous fiscal year, when performance was recovering from the impact of COVID-19. However, temporary losses led to an increase in other expenses, so the rise in operating profit was slight.

									(Billions of yen)
	Q1 (Apr.-Jun.)		Q2 (Jul.-Sep.)		Q3 (Oct.-Dec.)
			YoY change			YoY change			YoY change
		Ratio	(Previous period		Ratio	(Previous period		Radio	(Previous period =
			= 100%)			= 100%)			100%)
Net sales	79.3	100.0%	131.2%	89.3	100.0%	124.9%	90.1	100.0%	113.0%
Cost of sales	37.4	47.2%	125.4%	41.4	46.4%	118.8%	42.5	47.2%	110.8%
SG&A expenses	21.5	27.1%	113.6%	22.5	25.2%	117.8%	23.1	25.7%	115.2%
R&D expenses	5.4	6.9%	111.8%	6.1	6.8%	126.5%	6.7	7.4%	121.4%
Other income	0.1	0.2%	92.4%	(0.5)	(0.7)%	－	(1.5)	(1.7)%	－
(expenses)
Operating profit	15.0	19.0%	216.3%	18.6	20.9%	143.0%	16.1	17.9%	101.6%
Profit attributable to	9.9	12.6%	222.7%	12.2	13.7%	150.0%	10.6	11.8%	100.2%
owners of the parent

4

Breakdown of Net Sales (by Destination)

Net Sales by Destination

		(Billions of yen)
				FX
			impact
	APJapan		15.3
EMEA China
3.3	5.9

Americas 11.8 -0.09 10.6

258.9

211.8

+¥47.0 billion

2021 (First nine months of years to March 31)

2022

Sales rose by double digits on a local currency basis in all regions except China, due mainly to increased sales of hematology reagents.

		First nine months of fiscal year	YoY
	(Billions of yen)	ending March 31, 2022	(Previous period = 100%)
		Results	Ratio	Yen basis	Local currency
		basis
	Net sales	258.9	100.0%	122.2%		115.0%*
	Americas	59.2	22.9%	129.9%		123.9%
	EMEA	76.1	29.4%	127.8%		119.9%
	China	62.7	24.3%	111.3%		100.0%
	AP	21.3	8.3%	126.2%		119.7%*
	Japan	39.2	15.1%	118.0%		-

* Year-on-year increase on a yen basis, excluding the impact of exchange rate fluctuations

5